Previous 10 | Next 10 |
2023-11-28 09:38:56 ET More on NeuroSense Therapeutics NeuroSense: A Hold Ahead Of Phase 2b ALS Data NeuroSense ends equity offering, says it's fully funded into Q2 2024 NeuroSense secures patents in Europe, Japan, and Israel for its ALS drug PrimeC Seeking A...
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who c...
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness PR Newswire Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 ...
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 PR Newswire Clinical efficacy results ( s econdary endpoints) and safety results (primary endpoints) expe...
NeuroSense Therapeutics to Participate in BIO-Europe Fall PR Newswire CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today anno...
HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive disorder that affects motor neurons, le...
NeuroSense CEO Provides Q3 2023 Update PR Newswire Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass. , Oct. 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatm...
2023-10-06 18:51:15 ET Summary NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company’s most pivotal event since its IPO at the end of 2021. The company is also targeting...
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model PR Newswire In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neuron...
2023-10-02 09:57:53 ET More on NeuroSense Therapeutics NeuroSense secures patents in Europe, Japan, and Israel for its ALS drug PrimeC Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financia...
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...